As per the attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Rajnish Wellness Limited's Board approved its audited financial results for Q4 and FY25 on May 30, 2025, with the auditor (Motilal & Associates LLP) issuing an unmodified opinion. Revenue from operations fell sharply to Rs 4,856.11 lakhs in FY25 from Rs 7,668.46 lakhs in FY24, a decline of about 37%. Profit after tax dropped to Rs 17.30 lakhs from Rs 103.32 lakhs, while Q4 FY25 alone slipped into a loss with a PAT of Rs (45.89) lakhs versus a Rs 28.27 lakh profit in Q4 FY24. The company did not recommend any dividend for FY25. On the balance sheet, total assets shrank to Rs 9,128.35 lakhs, while borrowings fell sharply from Rs 374.61 lakhs to Rs 17.56 lakhs, and operating cash flow turned positive at Rs 170.39 lakhs versus a Rs 424.62 lakh outflow last year.
Shareholders should note a steep revenue and profit decline, with a loss-making Q4, though the balance sheet improved significantly with reduced debt and a return to positive operating cash flow. The weak earnings could weigh on the stock in the near term despite cleaner financials.